# New Clinical End-points in Patients With Primary Sjögren's Syndrome

> **NCT05113004** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 300 (estimated)

## Conditions studied

- Primary Sjögren's Syndrome (pSS)

## Interventions

- **DRUG:** Hydroxychloroquine 400mg/d
- **DRUG:** Leflunomide 20mg/d
- **DRUG:** Mycophenolate mofetil 2000mg/d
- **DRUG:** Placebo of Hydroxychloroquine 400mg/d
- **DRUG:** Placebo of Leflunomide 20mg/d
- **DRUG:** Placebo of Mycophenolate mofetil 2000mg/d

## Key facts

- **NCT ID:** NCT05113004
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-20
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113004, "New Clinical End-points in Patients With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05113004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*